SpeeDx (ASX:SX)

Executive Summary

SpeeDx Ltd is an Australian molecular diagnostics company that develops and commercialises multiplex qPCR assays using its proprietary Plex PCR platform. The company focuses on infectious disease testing, including respiratory viruses, sexually transmitted infections, and gastroenteritis, delivering rapid, high‑throughput, resistance‑guided diagnostics for clinical laboratories. Founded in 2014 and listed on the ASX (ticker: SX), SpeeDx has raised $80 million to advance its product pipeline and commercial presence. The company’s Plex PCR technology enables simultaneous detection of multiple pathogens and antimicrobial resistance markers in a single test, addressing a growing clinical need for rapid, actionable results. While competition from established players such as Cepheid and BioMérieux is intense, SpeeDx differentiates through its high-throughput, low-cost multiplexing capability and focus on resistance-guided therapy. The company is well-positioned to benefit from the global shift toward syndromic testing and decentralized diagnostics. Near-term growth is expected to be driven by expansion of its test menu, geographic diversification, and strategic partnerships. Key financial performance indicators, including revenue growth and assay adoption rates, will be closely monitored by investors.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE-IVDR certification for expanded respiratory panel70% success
• Q4 2026Strategic distribution agreement with a major US or European laboratory network60% success
• Q2 2026Publication of positive clinical data for antimicrobial resistance (AMR) assay80% success